Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 19:9:193.
doi: 10.3389/fnagi.2017.00193. eCollection 2017.

Microglial Activation in the Pathogenesis of Huntington's Disease

Hui-Ming Yang  1 , Su Yang  2 , Shan-Shan Huang  3 , Bei-Sha Tang  1   4   5   6 , Ji-Feng Guo  1   4   5   6
Affiliations
Review

Microglial Activation in the Pathogenesis of Huntington's Disease

Hui-Ming Yang et al. Front Aging Neurosci. .

Abstract

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by expanded CAG trinucleotide repeats (>36) in exon 1 of HTT gene that encodes huntingtin protein. Although HD is characterized by a predominant loss of neurons in the striatum and cortex, previous studies point to a critical role of aberrant accumulation of mutant huntingtin in microglia that contributes to the progressive neurodegeneration in HD, through both cell-autonomous and non-cell-autonomous mechanisms. Microglia are resident immune cells in the central nervous system (CNS), which function to surveil the microenvironment at a quiescent state. In response to various pro-inflammatory stimuli, microglia become activated and undergo two separate phases (M1 and M2 phenotype), which release pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), anti-inflammatory cytokines, and growth factors (TGF-β, CD206, and Arg1), respectively. Immunoregulation by microglial activation could be either neurotoxic or neuroprotective. In this review, we summarized current understanding about microglial activation in the pathogenesis and progression of HD, with a primary focus of M1 and M2 phenotype of activated microglia and their corresponding signaling pathways.

Keywords: Huntington’s disease; M1 phenotype; M2 phenotype; microglia; microglial activation; pathogenesis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bates G. P., Dorsey R., Gusella J. F., Hayden M. R., Kay C., Leavitt B. R., et al. (2015). Huntington disease. Nat. Rev. Dis. Primers 1 15005 10.1038/nrdp.2015.5 - DOI - PubMed
    1. Benito C., Nunez E., Tolon R. M., Carrier E. J., Rabano A., Hillard C. J., et al. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J. Neurosci. 23 11136–11141. - PMC - PubMed
    1. Benraiss A., Wang S., Herrlinger S., Li X. J., Chandler-Militello D., Mauceri J., et al. (2016). Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat. Commun. 7:11758 10.1038/ncomms11758 - DOI - PMC - PubMed
    1. Bisogno T., Oddi S., Piccoli A., Fazio D., Maccarrone M. (2016). Type-2 cannabinoid receptors in neurodegeneration. Pharmacol. Res. 111 721–730. 10.1016/j.phrs.2016.07.021 - DOI - PubMed
    1. Bjorkqvist M., Wild E. J., Thiele J., Silvestroni A., Andre R., Lahiri N., et al. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med. 205 1869–1877. 10.1084/jem.20080178 - DOI - PMC - PubMed